207 related articles for article (PubMed ID: 35593150)
1. Calcimimetics Alter Periosteal and Perilacunar Bone Matrix Composition and Material Properties in Early Chronic Kidney Disease.
Damrath JG; Moe SM; Wallace JM
J Bone Miner Res; 2022 Jul; 37(7):1297-1306. PubMed ID: 35593150
[TBL] [Abstract][Full Text] [Related]
2. Non-Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Damrath JG; Chen NX; Metzger CE; Srinivasan S; O'Neill K; Biruete A; Avin KG; Wallace JM; Allen MR; Moe SM
JBMR Plus; 2022 Mar; 6(3):e10600. PubMed ID: 35309859
[TBL] [Abstract][Full Text] [Related]
3. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
Swallow EA; Metzger CE; Newman CL; Chen NX; Moe SM; Allen MR
Bone; 2022 Apr; 157():116340. PubMed ID: 35085840
[TBL] [Abstract][Full Text] [Related]
4. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease.
Sharma S; Kumar S; Tomar MS; Chauhan D; Kulkarni C; Rajput S; Sadhukhan S; Porwal K; Guha R; Shrivastava A; Gayen JR; Kumar N; Chattopadhyay N
Bone; 2024 Aug; 185():117126. PubMed ID: 38777312
[TBL] [Abstract][Full Text] [Related]
5. Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.
Chen NX; Srinivasan S; O'Neill K; Nickolas TL; Wallace JM; Allen MR; Metzger CE; Creecy A; Avin KG; Moe SM
J Bone Miner Res; 2020 Mar; 35(3):608-617. PubMed ID: 31743501
[TBL] [Abstract][Full Text] [Related]
6. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
7. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
8. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
[TBL] [Abstract][Full Text] [Related]
10. Dentoalveolar Alterations in an Adenine-Induced Chronic Kidney Disease Mouse Model.
Mohamed FF; Amadeu de Oliveira F; Kinoshita Y; Yalamanchili RR; Eltilib LA; Andras NL; Narisawa S; Tani T; Chu EY; Millán JL; Foster BL
J Bone Miner Res; 2023 Aug; 38(8):1192-1207. PubMed ID: 37191192
[TBL] [Abstract][Full Text] [Related]
11. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management.
Pazianas M; Miller PD
J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482
[TBL] [Abstract][Full Text] [Related]
12. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
[TBL] [Abstract][Full Text] [Related]
13. Research on kidney and mineral metabolism in Japan: past, present, and future.
Mizobuchi M; Ogata H; Koiwa F; Kinugasa E; Akizawa T
Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):4-8. PubMed ID: 28005175
[TBL] [Abstract][Full Text] [Related]
14. Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.
Newman CL; Creecy A; Granke M; Nyman JS; Tian N; Hammond MA; Wallace JM; Brown DM; Chen N; Moe SM; Allen MR
Kidney Int; 2016 Jan; 89(1):95-104. PubMed ID: 26489025
[TBL] [Abstract][Full Text] [Related]
15. Examining the influence of PTH(1-34) on tissue strength and composition.
Gardinier JD; Al-Omaishi S; Rostami N; Morris MD; Kohn DH
Bone; 2018 Dec; 117():130-137. PubMed ID: 30261327
[TBL] [Abstract][Full Text] [Related]
16. Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1-34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition.
Taylor EA; Donnelly E; Yao X; Johnson ML; Amugongo SK; Kimmel DB; Lane NE
Calcif Tissue Int; 2020 Mar; 106(3):303-314. PubMed ID: 31784772
[TBL] [Abstract][Full Text] [Related]
17. The Dietary Fiber Inulin Slows Progression of Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) in a Rat Model of CKD.
Biruete A; Chen NX; Metzger CE; Srinivasan S; O'Neill K; Fallen PB; Fonseca A; Wilson HE; de Loor H; Evenepoel P; Swanson KS; Allen MR; Moe SM
JBMR Plus; 2023 Dec; 7(12):e10837. PubMed ID: 38130753
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.
Pazianas M; Miller PD
Am J Kidney Dis; 2021 Oct; 78(4):582-589. PubMed ID: 33774081
[TBL] [Abstract][Full Text] [Related]
19. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
